Related Experiment Videos
Reversible contractile dysfunction of viable myocardium. Implications for decision making process in post-infarction
R Scognamiglio1, G Fasoli, S Nistri
1Department of Cardiology, Medical School, University of Padua.
Insights
Detecting viable myocardium using post-extrasystolic potentiation (PESP) is crucial after myocardial infarction. This method identifies patients at risk of mortality and those who may benefit from revascularization, especially with low ejection fraction.
Area of Science:
- Cardiology
- Echocardiography
- Myocardial Viability Assessment
Background:
- Myocardial dysfunction and silent ischemia are key prognostic factors post-acute myocardial infarction (MI), even in low-risk patients.
- Impaired left ventricular function after MI stems from scar tissue and reversible dysfunction in stunned or hibernating myocardium.
- Silent ischemia's persistence is independent of reversible contractile dysfunction in asymptomatic post-MI patients.
Purpose of the Study:
- To evaluate the utility of post-extrasystolic potentiation (PESP) in detecting viable myocardium in asynergic segments.
- To assess the relationship between myocardial viability, silent ischemia, and left ventricular remodeling post-MI.
- To determine if PESP can predict long-term mortality and identify candidates for revascularization.
Main Methods:
- Two-dimensional echocardiography with post-extrasystolic potentiation (PESP) monitoring.
- Assessment of myocardial viability in asynergic segments.
- Correlation of PESP findings with clinical status, silent ischemia, left ventricular dilatation, and long-term mortality.
Main Results:
- Reversible contractile dysfunction is common in asymptomatic post-MI patients before discharge.
- A progressive loss of myocardial viability and left ventricular dilatation occurs within the first year post-MI, linked to silent ischemia.
- PESP detection of viable myocardium in the at-risk arterial zone predicts 4-year mortality, especially in patients with low ejection fraction (<40%).
Conclusions:
- PESP is a valuable tool for identifying viable myocardium in post-MI patients.
- Preserving viable myocardium is critical to prevent left ventricular remodeling and improve long-term prognosis.
- PESP findings can guide revascularization decisions in post-MI patients, particularly those with reduced ejection fraction.
Abstract:
Myocardial dysfunction and silent myocardial ischemia have been identified as important prognostic factors following acute myocardial infarction, also in low risk patients. In postinfarction patients, impaired left ventricular function is the result of fixed scar and reversible contractile dysfunction of viable stunning or hibernating myocardium. Post-extrasystolic potentiation (PESP) during 2-dimensional echocardiographic monitoring may be used to detect the presence of viable myocardium in asynergic myocardial segments. Incidence of reversible contractile dysfunction is a very common phenomenon at predischarge examination after myocardial infarction in asymptomatic patients, and it is independent on the persistence of silent ischemia. A progressive loss of myocardial viability occurs over the first year following the acute phase despite the maintenance of an asymptomatic clinical status. This phenomenon is associated with significant dilatation of the left ventricle. Moreover, silent ischemia is strongly related with this progressive loss of myocardial viability and left ventricular dilatation. Thus, it becomes evident that the most important role of medical and interventional approaches consists of limiting the acute necrosis by reperfusion and in preventing the loss of viable chronically hypoperfused myocardium that appears to be a major factor of left ventricular remodeling and changes over time of prognostication in individual patients. Finally, the presence of viable myocardium by PESP in the arterial zone at risk is highly predictive of 4-year mortality, particularly in patients with low ejection fraction (< 40%), and identifies patients who are suitable candidates for revascularization after myocardial infarction.